Chemotherapy
Long-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report
Cureus 2026 June 1 [Link] Shohei Otsuka, Kei Hiraoka, Nozomu Iwashiro Abstract Nivolumab is recommended as second-line therapy for malignant pleural mesothelioma (MPM); however, durable responses remain uncommon. In addition, combination immune checkpoint inhibitors are frequently limited by immune-related adverse events. A 72-year-old man with epithelioid MPM underwent extrapleural pneumonectomy followed by adjuvant chemotherapy with…
Read MoreImpact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study
In Vivo 2026 July-August [Link] Yusuke Nabe, Yasuhiro Fujita, Teppei Hashimoto, Kanji Tanaka, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Yohei Honda, Masataka Mori, Hiroki Matsumiya, Masatoshi Kanayama, Akihiro Taira, Masaru Takenaka, Koji Kuroda, Shohei Shimajiri, Fumihiro Tanaka Abstract Background/aim: While CD73 and CD155 are implicated in immune evasion and tumor progression,…
Read MoreCase Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma
Frontiers in Oncology 2026 June 16 [Link] Zijuan Liu, Yating Yan, Caihong Jiang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is an exceedingly rare and highly malignant tumor that originates in the serosal layer of the pericardium. Currently, there are no specific guidelines for diagnosis and treatment in China and international countries for this disease,…
Read MoreOutcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Clinical Lung Cancer 2026 July 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos Abstract…
Read MoreOutcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Clinical Lung Cancer 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos Abstract Background: There…
Read MoreCHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma
Clinical Lung Cancer 2026 July [Link] Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana Calabrò, Francesco Callegarin, Paola Del Bianco, Gian Luca De Salvo, Federica Pezzuto, Fiorella Calabrese, Valentina Guarneri, Andrea Dell’Amore, Federico Rea Abstract Pleural mesothelioma (PM) is…
Read MorePressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma- ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC)
Journal of Thoracic Disease 2026 May 31 [Link] Katharina Flöthmann, Norman Zinne, Peter Braubach, Alina Meininger, Imke Becker, Nicole Ernst, Arjang Ruhparwar, Hayan Merhej, Patrick Zardo Abstract Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with poor prognosis and limited treatment options. Pressurized intrathoracic aerosol chemotherapy (PITAC) has emerged as a novel…
Read MoreThe Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves
Current Oncology Reports 2026 June 8 [Link] Mehmet Kucukoner, Tarik Demir, Abduljalil Mohammed Alsubaie, Ulas Alabalik, Aisha K Ibrahim, Mariaelena Pierobon, Lance Liotta Abstract Purpose of review: Malignant pleural mesothelioma (MPM) remains a rare but highly aggressive malignancy with limited treatment options and poor prognosis. For nearly twenty years, platinum-pemetrexed chemotherapy has persisted as the…
Read MoreProtein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells
Cellular Oncology 2026 June 8 [Link] Eleonora Nigliato, Yan Ma, Rita Derua, Maria Butyrin, Sandra P Nunes, Léa Guilmot, Antonio De Gianni, Rüveyda Dok, Andrew P Feld, Michael Ohlmeyer, Brian E Wadzinski, Sandra Nuyts, Ilaria Elia, Anna Sablina, Veerle Janssens Abstract Purpose: Malignant pleural mesothelioma (MPM) is a rare cancer of the pleura, frequently related…
Read MoreA single-center experience in parenchyma-sparing surgical treatment of malignant pleural mesothelioma
Updates in Surgery 2026 June 1 [Link] Giuseppe Mangiameli, Debora Brascia, Emanuela Re Cecconi, Veronica Maria Giudici, Edoardo Bottoni, Alessandro Crepaldi, Umberto Cariboni, Alberto Testori, Paolo Zucali, Matteo Perrino, Nadia Cordua, Armando Santoro, Marco Alloisio, Giuseppe Marulli Abstract The role of surgery in malignant pleural mesothelioma (MPM) remains controversial, particularly after the negative results of…
Read More
Skip to content